Apolipoprotein B (ApoB)

Metabolic

Lipid Metabolism

mg/dL

Apolipoprotein B (ApoB) is a structural protein carried by every atherogenic lipoprotein — LDL, VLDL, IDL and Lp(a) — with exactly one ApoB-100 molecule per particle. Measuring ApoB therefore counts the total number of cholesterol-carrying particles capable of entering and damaging the arterial wall, making it the most direct blood measure of atherogenic particle burden. Two people with identical LDL-C can carry very different particle numbers, so ApoB frequently reclassifies cardiovascular risk that a standard lipid panel misses.

What It Measures

One ApoB molecule per atherogenic particle (LDL, VLDL, IDL, Lp(a)); best single marker of cardiovascular risk

Optimal vs. Lab Range

Longevity Optimal

Risk-stratified (NLA 2024): <90 mg/dL intermediate risk; <70 mg/dL high risk; <60 mg/dL very-high risk

Target range for optimal health and longevity based on research.

Standard Lab

<130 mg/dL (conventional 'high' threshold; population reference varies by lab)

Population-based reference range from standard labs.

Why It Matters

Large Mendelian randomization and cohort analyses establish ApoB-containing particle number as a causal driver of atherosclerotic cardiovascular disease and arguably the single best lipid predictor of risk. In its 2024 Expert Clinical Consensus, the National Lipid Association concluded that ApoB (and non-HDL-C) stratify ASCVD risk more accurately than LDL-C, especially when the two are discordant — common in insulin resistance, high triglycerides and metabolic syndrome. For a longevity-oriented practice, cumulative lifetime exposure to ApoB particles (not a single snapshot) shapes arterial aging, so measuring and lowering it early compounds benefit over decades.

When Low

Abetalipoproteinemia (extremely rare genetic condition)

When Optimal

Low atherogenic particle burden; each lower increment of ApoB is associated with proportionally lower atherosclerotic risk. Optimal targets are risk-stratified (see ranges).

When High

Atherosclerosis, myocardial infarction, stroke risk; each ApoB particle can enter arterial wall and initiate plaque

How to Optimize

ApoB tracks particle number, so strategies that lower atherogenic lipoproteins lower ApoB: reduced saturated and refined-carbohydrate intake, increased viscous fiber, weight and visceral-fat reduction, and regular aerobic plus resistance exercise. When lifestyle is insufficient for the individual's risk, evidence-based pharmacotherapy (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors) markedly reduces ApoB. Retest 6–12 weeks after any change. Treatment intensity and targets are individualized with your physician; this content is educational and not a substitute for medical advice.

Key Interventions & Linked Compounds

Strong evidence

Key Interventions

Statin (clinical)

PCSK9 inhibitor (clinical)

ezetimibe

bempedoic acid

exercise

low-carb diet

Linked Compounds & Supplements

Plant sterols

Berberine

Red yeast rice

Omega-3

Citrus bergamot

Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

Ordering Notes

Specimen

Serum or plasma (venous draw)

Patient prep

No fasting required. Maintain usual diet and medications unless advised.

Recommended cadence

Annual

Reporting unit

mg/dL

Pre-analytic notes

Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

Recommended Follow-Up Actions

1
Confirm the result is reliable
Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift Apolipoprotein B (ApoB).
2
Compare against optimal, not just lab range
Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.
3
Pair with related markers
Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.
4
Discuss interventions with a clinician
Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.
5
Re-test on a defined cadence
If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.